Whole body vibration marketing: bone, weight loss and circulation claims

Vibration platforms are sold in gyms, physical therapy and chiropractic offices, weight loss clinics, menopause and longevity practices, and wellness studios. The ads lean on a few big promises: “builds bone density,” “prevents osteoporosis,” “burns fat while you stand,” “boosts circulation and lymphatic drainage,” “10 minutes equals an hour at the gym.” The FDA record for vibration and bone is real but narrow, and it does not involve a whole body platform at all.

This guide covers the FDA device categories that use vibration, what FDA’s one bone-related authorization for a vibration device actually says, how the general wellness policy fits gym use, and how FTC rules apply to bone, weight, circulation and fitness claims, reviews and memberships. We do not name any device, brand or company.

The short version

• No FDA record for platforms and bone. We found no FDA product code, clearance or authorization for a whole body vibration platform for bone, weight or circulation.
• One narrow bone authorization exists, for a different device. In 2024 FDA granted a De Novo for a prescription wearable vibration belt for postmenopausal women with osteopenia. It is not for osteoporosis, fracture risk was not studied, and the effect was seen only for patients who used it as directed for one year.
• Therapeutic vibrators are a minor aches category. 21 CFR 890.5975 covers hand-held or attached vibrators for relaxing muscles and relieving minor aches and pains.
• Fitness wording is the safe ground. The general wellness policy covers physical fitness and relaxation claims without reference to disease.
• FTC rules apply to everything else. Bone density, osteoporosis, fat loss, circulation and lymphatic claims need competent and reliable scientific evidence.

The FDA categories that involve vibration

A search of FDA’s classification records through openFDA (device data last updated October 19, 2026) for vibration devices returned codes for specific medical uses, from a vibratory accessory for orthodontics to a vibrating mattress pad for infants in opioid withdrawal. Two matter for this guide:

• Therapeutic vibrator, 21 CFR 890.5975 (product code IRO). An electrically powered device intended for medical purposes, with pads, held in the hand or attached to the hand or a table, for uses such as relaxing muscles and relieving minor aches and pains. Class I and exempt from premarket notification. openFDA lists 65 older 510(k) decisions under IRO, the most recent from February 1996.
• Wearable vibration device for orthopedic use, 21 CFR 888.5895 (product code QZO). A wearable device that uses mechanical vibrations targeted to specific regions of the skeleton to reduce loss of bone strength or bone mineral density. Created by FDA’s De Novo grant DEN230015 on January 12, 2024. It is the only decision openFDA lists under that code.

A search of 510(k) decisions for “whole body vibration” or vibration platforms returned no results. A standing platform is not a hand-held therapeutic vibrator, and it is not a wearable device targeted to specific regions of the skeleton.

What FDA’s bone authorization actually says

The De Novo decision summary for DEN230015 is a useful benchmark, because it shows what FDA accepted for a vibration device and bone, and how carefully that result is fenced in. The device is a prescription wearable belt that sends low-amplitude vibration of 20 to 40 Hz to the spine and hips. Its indication is to reduce the decline in bone strength and volumetric bone density, measured by CT, in postmenopausal women with osteopenia of the lumbar spine or total hip (a DXA T-score between -1.0 and -2.49).

The limitations in the summary are specific:

• The device is not indicated for patients with osteoporosis.
• Clinical effects were observed only for the one-year length of the study.
• Fracture risk was not evaluated, so it is not known how the effect relates to fractures.
• Effects were shown only for people who used the device as indicated. Statistical significance was reached only for those who used it at least three times a week for 24 minutes, and 57.9% (73 of 126) of randomized patients completed the study per protocol.
• Most participants were white women without high-risk factors such as heavy smoking, type 1 diabetes, kidney disease or past fractures, and people with a BMI over 35 were not studied.

The size of the effect matters too. Patients who used the device per protocol lost 0.48% of vertebral bone strength over the year, compared with 2.84% in the sham group, and 0.29% of volumetric bone density compared with 1.97%. FDA called these indirect measures of benefit, not fracture outcomes, and noted increased back pain, dizziness and muscle weakness in the active group.

For a clinic or gym with a whole body platform, the lesson is direct: FDA’s one bone authorization for vibration is for a different device, a narrow population and a modest slowing of loss. It does not support “builds bone,” “reverses osteoporosis” or “prevents fractures” for a platform. Our guide to osteoporosis clinic marketing covers the wider bone health market.

Gyms, fitness claims and the general wellness policy

FDA’s guidance General Wellness: Policy for Low Risk Devices (issued January 6, 2026) describes low-risk products whose intended use is limited to general wellness, including physical fitness and relaxation or stress management, without reference to disease. A gym that offers platform sessions as a form of exercise is closest to that category.

The guidance also sets limits. If a product’s intended uses go beyond the general wellness categories, the guidance does not apply, and falling under the policy does not establish that a product has been shown to be safe or effective. Once a platform is promoted to treat osteoporosis, arthritis, neuropathy, lymphedema or poor circulation from a disease, it is no longer a fitness claim.

Fitness wording that stays within that line:

• “A standing exercise session on a vibration platform, guided by a trainer.”
• “Balance and strength exercises on a vibration platform as part of your workout.”
• “A relaxing session to wind down after training.”

Even fitness claims have to be true. “Ten minutes equals an hour of exercise” is an objective, measurable claim that needs evidence.

Bone, weight, circulation and lymph claims under FTC rules

Section 5 of the FTC Act declares unfair or deceptive acts or practices unlawful (15 USC 45(a)), and section 12 makes it unlawful to disseminate a false advertisement to induce the purchase of devices or services (15 USC 52). The FTC Health Products Compliance Guidance says health claims need competent and reliable scientific evidence, and the FTC reads an ad for its net impression.

• Bone. “Increases bone density,” “prevents osteoporosis” and “strengthens bones” are disease and structure claims. FDA’s own bone authorization was for a different device, with limits that a platform ad would leave out.
• Weight and fat. “Burns fat while you stand” and “lose inches in 10 minutes” are quantified weight claims that need evidence for your platform and protocol. Our guide to weight loss clinic marketing covers weight claims more broadly.
• Circulation and lymph. “Boosts circulation,” “drains your lymphatic system” and “detoxes” are claims about what happens inside the body. Tied to diabetes, lymphedema or vein disease, they become disease claims.
• Pain and conditions. “Relieves arthritis, fibromyalgia and back pain” names conditions. A therapeutic vibrator under 21 CFR 890.5975 is for minor aches and pains, not disease.
• Safety. “Safe for everyone” leaves out the side effects FDA noted for its own vibration belt and the people that study excluded.

Under 15 USC 55(a)(1), whether an ad is misleading also depends on what it fails to reveal. Tell clients who should check with a clinician first, such as people who are pregnant, have recent surgery, a joint replacement or an implanted device, and what to do if they feel dizzy. The vibration belt’s warnings listed spinal fusion, joint replacement implants and active implants among conditions to raise with a doctor first.

“FDA cleared” and “FDA registered” platforms

A supplier may describe a platform as “FDA registered” or “medical grade.” Registration is not approval: 21 CFR 807.39 says a registration number does not denote approval and that implying approval because of registration is misbranding. A 510(k) clearance is not approval either (21 CFR 807.97). Ask for the product code and any 510(k) or De Novo number in writing, read it in FDA’s databases, and repeat only what the record says, with its indication. Our guide to medical device marketing claims covers that wording.

Reviews, before-and-after photos and results

Under 16 CFR 255.2(a), an advertiser must have substantiation for what a consumer endorsement conveys, as if it made the claim itself. A featured review saying “my bone scan improved after six months on the platform” carries a bone density claim the business would need to support. Under 16 CFR 255.2(b), an endorsement about a central attribute is likely to be read as showing typical results unless the ad clearly and conspicuously discloses the generally expected results.

Body photos raise the same issue for weight claims. If the client also changed diet, training or medication, a caption that credits the platform alone is misleading. Get written authorization before posting any client image. See our guide to patient testimonials and before-and-after photos.

Memberships, packages and prices

• Say what a session is. Length, supervised or not, and what else is included.
• Memberships need plain terms. Price, renewal, cancellation and any minimum term, stated where the membership is sold.
• Former prices must be real. “Was $199 a month, now $99” needs a former price you actually offered in good faith for a reasonably substantial period (16 CFR 233.1(a)).
• No outcome bundles. “12 weeks to stronger bones” is both a package and a disease claim.

See our guides to advertising cash prices and money-back guarantees in healthcare ads.

An example (made up)

This illustration is invented. A studio posts: “FDA registered vibration platform! Rebuilds bone density, reverses osteoporosis and burns 3x more fat. Flushes your lymphatic system. 10 minutes equals a 1-hour workout. Safe for all ages. Was $249, now $79.”

Fixes: “FDA registered” comes off (21 CFR 807.39). “Rebuilds bone density” and “reverses osteoporosis” come off; FDA’s only bone authorization for a vibration device is for a different device and is not for osteoporosis. “3x more fat,” “flushes your lymphatic system” and “10 minutes equals a 1-hour workout” come off unless the studio holds competent and reliable scientific evidence for each. “Safe for all ages” becomes a short note on who should check with a clinician first. The former price stays only if clients actually paid $249 for a reasonable period. A version that works: “Trainer-led balance and strength sessions on a vibration platform. Check with your clinician first if you are pregnant, recently had surgery or have an implant.”

Checklist

• Know whether your platform has any FDA product code, 510(k) or De Novo, and read its indication; no “FDA approved” or “FDA registered” wording (21 CFR 807.39, 807.97).
• No bone density, osteoporosis or fracture claims for a platform; FDA’s bone authorization covers a different device with narrow limits (DEN230015).
• Fitness and relaxation wording only, within the general wellness policy (FDA guidance, January 6, 2026).
• Weight, fat, circulation, lymph and condition claims backed by competent and reliable scientific evidence, or removed (15 USC 45, 52; FTC guidance).
• Who should check with a clinician first stated near the booking button (15 USC 55(a)(1)).
• Reviews and photos do not say what the business could not say; typical results disclosed (16 CFR 255.2).
• Memberships, packages and former prices are real and clear (16 CFR 233.1).

How we help

We build service pages for physical therapy, chiropractic, menopause and weight loss practices with claims checked against the sources above: website design, healthcare SEO for searches like “vibration therapy near me,” and lead generation campaigns that describe vibration sessions without bone, fat or FDA overclaims. We do not decide whether a service works, we do not give legal opinions, and we are not a law firm. Related guides: PEMF therapy marketing rules, body contouring clinic marketing and physical therapy marketing ideas.

Sources

• openFDA device classification data (last updated October 19, 2026)
• openFDA device 510(k) data (last updated October 19, 2026)
• FDA product classification: IRO, Vibrator, therapeutic
• FDA product classification: QZO, Wearable vibration device for orthopedic use
• FDA De Novo decision summary: DEN230015 (granted January 12, 2024)
• 21 CFR 890.5975: Therapeutic vibrator
• 21 CFR 807.39: Misbranding by reference to establishment registration
• 21 CFR 807.97: Misbranding by reference to premarket notification
• FDA: General Wellness: Policy for Low Risk Devices (issued January 6, 2026)
• 15 USC 45: Unfair methods of competition unlawful
• 15 USC 52: Dissemination of false advertisements
• 15 USC 55: Additional definitions
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.2: Consumer endorsements
• 16 CFR 233.1: Former price comparisons

More in Cash-pay, aesthetic and wellness care